SAFINAMIDE MESYLATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for safinamide mesylate and what is the scope of patent protection?
Safinamide mesylate
is the generic ingredient in two branded drugs marketed by Aurobindo Pharma, Prinston Inc, and Mdd Us, and is included in three NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Safinamide mesylate has ninety-seven patent family members in thirty-one countries.
One supplier is listed for this compound.
Summary for SAFINAMIDE MESYLATE
International Patents: | 97 |
US Patents: | 3 |
Tradenames: | 2 |
Applicants: | 3 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 79 |
Patent Applications: | 68 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SAFINAMIDE MESYLATE |
What excipients (inactive ingredients) are in SAFINAMIDE MESYLATE? | SAFINAMIDE MESYLATE excipients list |
DailyMed Link: | SAFINAMIDE MESYLATE at DailyMed |
Pharmacology for SAFINAMIDE MESYLATE
Drug Class | Monoamine Oxidase Type B Inhibitor |
Mechanism of Action | Breast Cancer Resistance Protein Inhibitors Monoamine Oxidase-B Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for SAFINAMIDE MESYLATE
US Patents and Regulatory Information for SAFINAMIDE MESYLATE
International Patents for SAFINAMIDE MESYLATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Russian Federation | 2342929 | СПОСОБЫ ЛЕЧЕНИЯ БОЛЕЗНИ ПАРКИНСОНА (METHODS OF PARKINSON'S DISEASE TREATMENT) | ⤷ Subscribe |
Cyprus | 1115951 | ⤷ Subscribe | |
Germany | 602004021790 | ⤷ Subscribe | |
European Patent Office | 2070526 | Procedes de traitment de la maladie de Parkinson (Methods for treatment of Parkinson's disease) | ⤷ Subscribe |
Norway | 20131417 | ⤷ Subscribe | |
Cyprus | 1115286 | ⤷ Subscribe | |
Hungary | S1500043 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SAFINAMIDE MESYLATE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1613296 | 241 50017-2015 | Slovakia | ⤷ Subscribe | PRODUCT NAME: SAFINAMID; REGISTRATION NO/DATE: EU/1/14/984/001 - EU/1/14/984/010 20150226 |
1613296 | 46/2015 | Austria | ⤷ Subscribe | PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224 |
1613296 | CA 2015 00042 | Denmark | ⤷ Subscribe | PRODUCT NAME: KOMBINATION AF SAFINAMID OG LEVOPODA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150224 |
1613296 | 15C0054 | France | ⤷ Subscribe | PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224 |
1613296 | C20150033 00258 | Estonia | ⤷ Subscribe | PRODUCT NAME: SAFINAMIID;REG NO/DATE: EU/1/14/984 26.02.2015 |
1613296 | 300752 | Netherlands | ⤷ Subscribe | PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224 |
1613296 | CR 2015 00042 | Denmark | ⤷ Subscribe | PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
SAFINAMIDE MESYLATE Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.